NCT03845166: A Study of XL092 in Subjects With Solid Tumors

NCT03845166
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are not eligible for the expansion phase
Exclusions: Patients with known, untreated, unstable brain metastases – see trial for details
https://ClinicalTrials.gov/show/NCT03845166

Comments are closed.

Up ↑